Get started
Author

Nasrin Samji

Observed names: N Samji, N. Samji
ORCID: 0000-0002-6754-1261
Observed ORCID: 0000-0002-6754-1261
OpenAlex ID: A5058711052
Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options
2022 · Nasrin Samji, Mihir D. Bhatt, et al. · Frontiers in Pediatrics · 19
PDF
Use of thrombolytic agents to treat neonatal thrombosis in clinical practice
2022 · Russell Leong, Jay Patel, et al. · Blood Coagulation & Fibrinolysis · 19
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada
2023 · Kathelijn Fischer, Riitta Lassila, et al. · Research and Practice in Thrombosis and Haemostasis · 18
Management of children with hemophilia A on emicizumab who need surgery
2023 · Mark Belletrutti, Mihir Bhatt, et al. · Frontiers in Pediatrics · 10
PDF
Successful Use of Thrombolysis in an Extremely Low Birth Weight, Premature Infant With Aortic Thrombosis
2022 · Nasrin Samji, Jennifer Twiss, et al. · Journal of Pediatric Hematology/Oncology · 5
Desmoplastic Small Round Cell Tumor With Ascending Intraspinal Metastasis at Recurrence: Case Report and Review of the Literature
2021 · Chantel Cacciotti, Nasrin Samji, et al. · Journal of Pediatric Hematology/Oncology · 4
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
2026 · Margareth C. Ozelo, Matteo Luciani, et al. · European Journal Of Haematology · 3
PB2278 Population experience of pediatric cerebral sinovenous thrombosis in head and neck infections: a multi-institutional Canadian experience
2026 · Nasrin Samji, Mira F. Liebman, et al. · Research and Practice in Thrombosis and Haemostasis
Case Report: Atypical presentations of neonatal and infantile hemophilia B
2026 · Arielle Locke, Nasrin Samji, et al. · Frontiers in Pediatrics
PDF
Damoctocog alfa pegol in patients aged 7 to<12; an interim analysis of the Alfa-PROTECT extension
2026 · A K Chan, M C Ozelo, et al. · Hämostaseologie
Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
2026 · Margareth C. Ozelo, Matteo Luciani, et al. · European Journal Of Haematology
HTRS2025.O8C.3 Alfa-PROTECT: A Phase 3, Open-Label Study to Evaluate the Safety of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A
2025 · Margareth C. Ozelo, Anthony K.C. Chan, et al. · Research and Practice in Thrombosis and Haemostasis
PDF
HTRS2025.P1.9 Safety of Damoctocog Alfa Pegol in Patients With Severe Hemophilia A Aged 7 to <12 years of age; Pooled Data From PROTECT VIII Kids and Alfa-PROTECT
2025 · Margareth C. Ozelo, Anthony K.C. Chan, et al. · Research and Practice in Thrombosis and Haemostasis
Patient and Clinical Experience on Concizumab Clinical Trial: A Case Study
2024 · Karen Strike, Mihir Bhatt, et al. · Blood
PB0661 Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study
2023 · D. Matino, A. Iorio, et al. · Research and Practice in Thrombosis and Haemostasis
Works count: 15
Citation count: 78
H-index: 5
I10-index: 4
Year
Topic
Type